GIPC3

Across TCGA pan-cancer cohorts, GIPC3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GIPC3 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GIPC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GIPC3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where GIPC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.801	0.314	.004	16	view →
LSCC	DFS	Tertile	II,III,IV	0.891	1.000	.020	6	view →
HNSC	OS	Quartile	II,III,IV	0.889	0.603	.034	2	view →
PDAC	DFS	Tertile	III,IV	0.651	1.000	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GIPC3–CCRCC (DFS)

Open the CCRCC breakdown →